Compared with placebo , setipiprant significantly reduced the allergen-induced late asthmatic response ( LAR ) , inhibiting the area under the response vs. time curve ( AUC ( @-@ h ) ) by on average @ % ( P = @ ) and significantly protected against the allergen-induced airway hyperresponsiveness ( AHR ) to methacholine ( P = @ ) .